目的 探討當(dāng)歸龍薈片聯(lián)合普蘆卡必利治療慢性功能性便秘的臨床療效。方法 選取2018年5月-2019年5月在北京市肛腸醫(yī)院治療的慢性功能性便秘患者122例，根據(jù)用藥的差別分為對(duì)照組（61例）和治療組（61例）。對(duì)照組口服琥珀酸普蘆卡必利片，2 mg/次，1次/d；治療組在對(duì)照組基礎(chǔ)上口服當(dāng)歸龍薈片，4片/次，2次/d。兩組患者均經(jīng)4周治療。觀察兩組患者臨床療效，同時(shí)比較治療前后兩組患者臨床癥狀評(píng)分、PAC-QOL積分、結(jié)腸傳輸試驗(yàn)積分、Bristol和SF-36評(píng)分，及血清5-羥色胺（5-HT）、血管活性腸肽（VIP）、P物質(zhì)（SP）和一氧化氮（NO）水平。結(jié)果 治療后，對(duì)照組和治療組臨床有效率分別為80.33%和96.72%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。經(jīng)治療，兩組癥狀積分均明顯降低（P<0.05），且治療組比對(duì)照組降低更明顯（P<0.05）。經(jīng)治療，兩組患者PAC-QOL積分和結(jié)腸傳輸試驗(yàn)積分明顯降低（P<0.05），而B(niǎo)ristol和SF-36評(píng)分明顯升高（P<0.05），且治療組患者明顯好于對(duì)照組（P<0.05）。經(jīng)治療，兩組患者血清SP、5-HT水平均顯著升高（P<0.05），而VIP和NO水平均明顯降低（P<0.05），且治療組患者SP、5-HT、VIP和NO水平明顯優(yōu)于對(duì)照組（P<0.05）。結(jié)論 當(dāng)歸龍薈片聯(lián)合普蘆卡必利治療慢性功能性便秘可有效改善患者臨床癥狀，促進(jìn)患者生活質(zhì)量改善，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Danggui Longhui Tablets combined with procapril in treatment of chronic functional constipation. Methods Patients (122 cases) with chronic functional constipation in Beijing Rectum Hospital from May 2018 to May 2019 were divided into control (61 cases) and treatment (61 cases) groups based on different treatments. Patients in the control group were po administered with Prucalopride Succinate Tablets, 2 mg/time, once daily. Patients in the treatment group were po administered with Danggui Longhui Tablets on the basis of the control group, 4 tablets/time, twice daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the clinical symptom score, PAC-QOL score, colonic transit test score, Bristol and SF-36 score, and the serum level of 5-HT, VIP, SP and NO in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 80.33% and 96.72% respectively, and there were differences between two groups (P<0.05). After treatment, the clinical symptom score in two groups was significantly decreased (P<0.05), and which in the treatment group was significantly lower than that in the control group (P<0.05). After treatment, the PAC-QOL score and colonic transit test score in two groups were significantly decreased (P<0.05), but the Bristol and SF-36 score were significantly increased (P<0.05), and these scores in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the serum level of 5-HT and SP in two groups was significantly increased (P<0.05), but the VIP and NO level was significantly decreased (P<0.05), and the serum level of 5-HT, VIP, SP, and NO in the treatment group was significantly better than that in the control group (P<0.05). Conclusion Danggui Longhui Tablets combined with procapril in treatment of chronic functional constipation can effectively improve the clinical symptoms, and promote the improvement of quality of life, which has a certain clinical application value.

R975